Merck drug prevents serious infection after marrow transplant -study
February 23, 2017 at 13:51 PM EST
Feb 23 (Reuters) - An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late state study, the company said.